The latest price target for Novartis (NYSE:NVS) was reported by B of A Securities on September 11, 2024. The analyst firm set a price target for $130.00 expecting NVS to rise to within 12 months (a possible 11.76% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Novartis (NYSE:NVS) was provided by B of A Securities, and Novartis downgraded their neutral rating.

The last upgrade for Novartis AG happened on September 25, 2023 when Morgan Stanley raised their price target to N/A. Morgan Stanley previously had an underweight for Novartis AG.

The last downgrade for Novartis AG happened on September 11, 2024 when B of A Securities changed their price target from $135 to $130 for Novartis AG.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novartis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novartis was filed on September 11, 2024 so you should expect the next rating to be made available sometime around September 11, 2025.

While ratings are subjective and will change, the latest Novartis (NVS) rating was a downgraded with a price target of $135.00 to $130.00. The current price Novartis (NVS) is trading at is $116.32, which is out of the analyst’s predicted range.